3 курс / Фармакология / Интеллектуальные_липидные_наноконтейнеры_в_адресной_доставке_лекарственных
.pdf249
865.Ross J.F., Wang H., Behm F.G., Mathew P., Wu M., Booth R., Ratnam M. (1999) Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer, 85, 348-357.
866.Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski V.R., Jr., Kamen B.A. (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res., 52, 3396-3401.
867.Low P.S., Henne W.A., Doorneweerd D.D. (2008) Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc.Chem.Res., 41, 120-129.
868.Mathias C.J., Wang S., Waters D.J., Turek J.J., Low P.S., Green M.A. (1998) Indium- 111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J.Nucl.Med., 39, 1579-1585.
869.Campbell I.G., Jones T.A., Foulkes W.D., Trowsdale J. (1991) Folate-binding protein is a marker for ovarian cancer. Cancer Res., 51, 5329-5338.
870.Coney L.R., Tomassetti A., Carayannopoulos L., Frasca V., Kamen B.A., Colnaghi M.I., Zurawski V.R., Jr. (1991) Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res., 51, 6125-6132.
871.Gabizon A., Shmeeda H., Horowitz A.T., Zalipsky S. (2004) Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv.Drug Deliv.Rev., 56, 1177-1192.
872.Gibbs D.D., Theti D.S., Wood N., Green M., Raynaud F., Valenti M., Forster M.D., Mitchell F., Bavetsias V., Henderson E., Jackman A.L. (2005) BGC 945, a novel tumorselective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res., 65, 11721-11728.
873.Lu Y., Low P.S. (2002) Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv.Drug Deliv.Rev., 54, 675-693.
874.Salazar M.D., Ratnam M. (2007) The folate receptor: what does it promise in tissuetargeted therapeutics? Cancer Metastasis Rev., 26, 141-152.
875.Jackman A.L., Theti D.S., Gibbs D.D. (2004) Antifolates targeted specifically to the folate receptor. Adv.Drug Deliv.Rev., 56, 1111-1125.
876.Nagayoshi R., Nakamura M., Ijiri K., Yoshida H., Komiya S., Matsuyama T. (2003) LY309887, antifolate via the folate receptor suppresses murine type II collagen-induced arthritis. Clin.Exp.Rheumatol., 21, 719-725.
877.Theti D.S., Bavetsias V., Skelton L.A., Titley J., Gibbs D., Jansen G., Jackman A.L. (2003) Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor. Cancer Res., 63, 3612-3618.
878.Turek J.J., Leamon C.P., Low P.S. (1993) Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J.Cell Sci., 106, 423-430.
879.Leamon C.P., Pastan I., Low P.S. (1993) Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J.Biol.Chem., 268, 24847-24854.
880.Yang J., Chen H., Vlahov I.R., Cheng J.X., Low P.S. (2006) Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging.
Proc.Natl.Acad.Sci.U.S.A, 103, 13872-13877.
881.Rijnboutt S., Jansen G., Posthuma G., Hynes J.B., Schornagel J.H., Strous G.J. (1996) Endocytosis of GPI-linked membrane folate receptor-alpha. J.Cell Biol., 132, 35-47.
882.Low P.S., Antony A.C. (2004) Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv.Drug Deliv.Rev., 56, 1055-1058.
883.Kamen B.A., Caston J.D. (1986) Properties of a folate binding protein (FBP) isolated from porcine kidney. Biochem.Pharmacol., 35, 2323-2329.
884.da Costa M., Rothenberg S.P. (1996) Purification and characterization of folate binding proteins from rat placenta. Biochim.Biophys.Acta, 1292, 23-30.
885.Leamon C.P., Low P.S. (1993) Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells. Biochem.J., 291, 855-860.
886.Leamon C.P., Low P.S. (1992) Cytotoxicity of momordin-folate conjugates in cultured human cells. J.Biol.Chem., 267, 24966-24971.
250
887.Ni S., Stephenson S.M., Lee R.J. (2002) Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res., 22, 2131-2135.
888.Pan X.Q., Wang H., Lee R.J. (2003) Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm.Res., 20, 417-
889.Stephenson S.M., Yang W., Stevens P.J., Tjarks W., Barth R.F., Lee R.J. (2003) Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy.
Anticancer Res., 23, 3341-3345.
890.Reddy J.A., Abburi C., Hofland H., Howard S.J., Vlahov I., Wils P., Leamon C.P. (2002) Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther., 9, 1542-1550.
891.Leamon C.P., Cooper S.R., Hardee G.E. (2003) Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug.Chem., 14, 738-747.
892.Lee R.J., Low P.S. (1994) Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J.Biol.Chem., 269, 3198-3204.
893.Henne W.A., Doorneweerd D.D., Hilgenbrink A.R., Kularatne S.A., Low P.S. (2006) Synthesis and activity of a folate peptide camptothecin prodrug. Bioorg.Med.Chem.Lett., 16, 5350-5355.
894.Fan J.G., Pope L.E., Vitols K.S., Huennekens F.M. (1991) Affinity labeling of folate transport proteins with the N-hydroxysuccinimide ester of the gamma-isomer of fluoresceinmethotrexate. Biochemistry, 30, 4573-4580.
895.Fan J., Pope L.E., Vitols K.S., Huennekens F.M. (1990) Visualization of folate transport proteins by covalent labeling with fluorescein methotrexate. Adv.Enzyme Regul., 30, 3-12.
896.Mathias C.J., Lewis M.R., Reichert D.E., Laforest R., Sharp T.L., Lewis J.S., Yang Z.F., Waters D.J., Snyder P.W., Low P.S., Welch M.J., Green M.A. (2003) Preparation of 66Gaand 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nucl.Med.Biol., 30, 725-731.
897.Trump D.P., Mathias C.J., Yang Z., Low P.S., Marmion M., Green M.A. (2002) Synthesis and evaluation of 99mTc(CO)(3)-DTPA-folate as a folate-receptor-targeted radiopharmaceutical. Nucl.Med.Biol., 29, 569-573.
898.Mathias C.J., Hubers D., Low P.S., Green M.A. (2000) Synthesis of [(99m)Tc]DTPAfolate and its evaluation as a folate-receptor-targeted radiopharmaceutical. Bioconjug.Chem., 11, 253-257.
899.Mathias C.J., Wang S., Low P.S., Waters D.J., Green M.A. (1999) Receptor-mediated targeting of 67Ga-deferoxamine-folate to folate-receptor-positive human KB tumor xenografts. Nucl.Med.Biol., 26, 23-25.
900.Wang S., Luo J., Lantrip D.A., Waters D.J., Mathias C.J., Green M.A., Fuchs P.L., Low P.S. (1997) Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjug.Chem., 8, 673-679.
901.Lee R.J., Low P.S. (1995) Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim.Biophys.Acta, 1233, 134-144.
902.Zhao X.B., Muthusamy N., Byrd J.C., Lee R.J. (2007) Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes. J.Pharm.Sci., 96, 2424-2435.
903.Gabizon A., Horowitz A.T., Goren D., Tzemach D., Mandelbaum-Shavit F., Qazen M.M., Zalipsky S. (1999) Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug.Chem., 10, 289-298.
904.Lee R.J., Wang S., Turk M.J., Low P.S. (1998) The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery.
Biosci.Rep., 18, 69-78.
905.Reddy J.A., Low P.S. (2000) Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J.Control Release, 64, 27-37.
906.Turk M.J., Reddy J.A., Chmielewski J.A., Low P.S. (2002) Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim.Biophys.Acta, 1559, 56-68.
251
907.Lu Y., Wu J., Wu J., Gonit M., Yang X., Lee A., Xiang G., Li H., Liu S., Marcucci G., Ratnam M., Lee R.J. (2007) Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol.Pharm., 4, 707-
908.Pan X.Q., Lee R.J. (2005) In vivo antitumor activity of folate receptor-targeted liposomal daunorubicin in a murine leukemia model. Anticancer Res., 25, 343-346.
909.Sudimack J.J., Guo W., Tjarks W., Lee R.J. (2002) A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim.Biophys.Acta, 1564, 31-37.
910.Wu J., Liu Q., Lee R.J. (2006) A folate receptor-targeted liposomal formulation for paclitaxel. Int.J.Pharm., 316, 148-153.
911.Sudimack J.J., Adams D., Rotaru J., Shukla S., Yan J., Sekido M., Barth R.F., Tjarks W., Lee R.J. (2002) Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapy. Pharm.Res., 19, 1502-1508.
912.Stevens P.J., Sekido M., Lee R.J. (2004) Synthesis and evaluation of a hematoporphyrin derivative in a folate receptor-targeted solid-lipid nanoparticle formulation. Anticancer Res., 24, 161-165.
913.Chiu S.J., Marcucci G., Lee R.J. (2006) Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes. Anticancer Res., 26, 10491056.
914.Goren D., Horowitz A.T., Tzemach D., Tarshish M., Zalipsky S., Gabizon A. (2000) Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrugresistance efflux pump. Clin.Cancer Res., 6, 1949-1957.
915.Xu L., Pirollo K.F., Chang E.H. (2001) Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J.Control Release, 74, 115-128.
916.Reddy J.A., Dean D., Kennedy M.D., Low P.S. (1999) Optimization of folateconjugated liposomal vectors for folate receptor-mediated gene therapy. J.Pharm.Sci., 88, 1112-1118.
917.Gosselin M.A., Guo W., Lee R.J. (2002) Incorporation of reversibly cross-linked polyplexes into LPDII vectors for gene delivery. Bioconjug.Chem., 13, 1044-1053.
918.Hofland H.E., Masson C., Iginla S., Osetinsky I., Reddy J.A., Leamon C.P., Scherman D., Bessodes M., Wils P. (2002) Folate-targeted gene transfer in vivo. Mol.Ther., 5, 739-744.
919.Laine C., Mornet E., Lemiegre L., Montier T., Cammas-Marion S., Neveu C., Carmoy N., Lehn P., Benvegnu T. (2008) Folate-equipped pegylated archaeal lipid derivatives: synthesis and transfection properties. Chemistry., 14, 8330-8340.
920.Shi G., Guo W., Stephenson S.M., Lee R.J. (2002) Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. J.Control Release, 80, 309-319.
921.Wang S., Lee R.J., Cauchon G., Gorenstein D.G., Low P.S. (1995) Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.
Proc.Natl.Acad.Sci.U.S.A, 92, 3318-3322.
922.Jhaveri M.S., Rait A.S., Chung K.N., Trepel J.B., Chang E.H. (2004) Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol.Cancer Ther., 3, 1505-1512.
923.Zhao X.B., Lee R.J. (2004) Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv.Drug Deliv.Rev., 56, 1193-1204.
924.Yang L., Li J., Zhou W., Yuan X., Li S. (2004) Targeted delivery of antisense oligodeoxynucleotides to folate receptor-overexpressing tumor cells. J.Control Release, 95, 321-331.
925.Gabizon A., Horowitz A.T., Goren D., Tzemach D., Shmeeda H., Zalipsky S. (2003) In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Clin.Cancer Res., 9, 6551-6559.
926.Sofou S., Sgouros G. (2008) Antibody-targeted liposomes in cancer therapy and imaging. Expert.Opin.Drug Deliv., 5, 189-204.
927.Torchilin V. (2008) Antibody-modified liposomes for cancer chemotherapy.
Expert.Opin.Drug Deliv., 5, 1003-1025.
252
928.Gregoriadis G., Neerunjun E.D. (1975) Homing of liposomes to target cells.
Biochem.Biophys.Res.Commun., 65, 537-544.
929.Leserman L.D., Weinstein J.N., Blumenthal R., Sharrow S.O., Terry W.D. (1979) Binding of antigen-bearing fluorescent liposomes to the murine myeloma tumor MOPC 315. J.Immunol., 122, 585-591.
930.Leserman L.D., Barbet J., Kourilsky F., Weinstein J.N. (1980) Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature, 288, 602-604.
931.Leserman L.D., Machy P., Barbet J. (1981) Cell-specific drug transfer from liposomes bearing monoclonal antibodies. Nature, 293, 226-228.
932.Huwyler J., Cerletti A., Fricker G., Eberle A.N., Drewe J. (2002) By-passing of P- glycoprotein using immunoliposomes. J.Drug Target, 10, 73-79.
933.Torchilin V.P., Klibanov A.L., Huang L., O'Donnell S., Nossiff N.D., Khaw B.A. (1992) Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J., 6, 2716-2719.
934.Hansen C.B., Kao G.Y., Moase E.H., Zalipsky S., Allen T.M. (1995) Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim.Biophys.Acta, 1239, 133-144.
935.Allen T.M., Brandeis E., Hansen C.B., Kao G.Y., Zalipsky S. (1995) A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim.Biophys.Acta, 1237, 99-108.
936.Sapra P., Tyagi P., Allen T.M. (2005) Ligand-targeted liposomes for cancer treatment.
Curr.Drug Deliv., 2, 369-381.
937.Shahinian S., Silvius J.R. (2004) High-yield coupling of antibody Fab' fragments to liposomes containing maleimide-functionalized lipids. Methods Enzymol., 387, 3-15.
938.Mamot C., Drummond D.C., Noble C.O., Kallab V., Guo Z., Hong K., Kirpotin D.B., Park J.W. (2005) Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res., 65, 11631-11638.
939.Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., Park J.W. (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res., 66, 6732-6740.
940.Ishida T., Iden D.L., Allen T.M. (1999) A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett., 460, 129-133.
941.Iden D.L., Allen T.M. (2001) In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach.
Biochim.Biophys.Acta, 1513, 207-216.
942.Lukyanov A.N., Elbayoumi T.A., Chakilam A.R., Torchilin V.P. (2004) Tumortargeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J.Control Release, 100, 135-144.
943.Nellis D.F., Ekstrom D.L., Kirpotin D.B., Zhu J., Andersson R., Broadt T.L., Ouellette T.F., Perkins S.C., Roach J.M., Drummond D.C., Hong K., Marks J.D., Park J.W., Giardina S.L. (2005) Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol.Prog., 21, 205-220.
944.Nellis D.F., Giardina S.L., Janini G.M., Shenoy S.R., Marks J.D., Tsai R., Drummond D.C., Hong K., Park J.W., Ouellette T.F., Perkins S.C., Kirpotin D.B. (2005) Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol.Prog., 21, 221-232.
945.Drummond D.C., Noble C.O., Guo Z., Hong K., Park J.W., Kirpotin D.B. (2006) Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res., 66, 3271-3277.
946.Noble C.O., Krauze M.T., Drummond D.C., Yamashita Y., Saito R., Berger M.S., Kirpotin D.B., Bankiewicz K.S., Park J.W. (2006) Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res., 66, 2801-2806.
253
947.Elbayoumi T.A., Torchilin V.P. (2009) Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin.Cancer Res., 15, 1973-1980.
948.Elbayoumi T.A., Torchilin V.P. (2009) Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. Mol.Pharm., 6, 246-254.
949.Chiu G.N., Edwards L.A., Kapanen A.I., Malinen M.M., Dragowska W.H., Warburton C., Chikh G.G., Fang K.Y., Tan S., Sy J., Tucker C., Waterhouse D.N., Klasa R., Bally M.B. (2007) Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol.Cancer Ther., 6, 844-855.
950.Siddiqi T., Joyce R.M. (2008) A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin.Lymphoma Myeloma., 8, 300-304.
951.Lapalombella R., Yu B., Triantafillou G., Liu Q., Butchar J.P., Lozanski G., Ramanunni A., Smith L.L., Blum W., Andritsos L., Wang D.S., Lehman A., Chen C.S., Johnson A.J., Marcucci G., Lee R.J., Lee L.J., Tridandapani S., Muthusamy N., Byrd J.C. (2008) Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibodydependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood, 112, 5180-5189.
952.Garrido J., Labrador P.J., Lerma L., Heras M., Garcia P., Bondia A., Corbacho L., Tabernero M. (2004) Vascular Aspergillus infection in two recipients of kidneys from the same donor. Nefrologia., 24, 30-34.
953.Apostolidou E., Cortes J., Tsimberidou A., Estey E., Kantarjian H., Giles F.J. (2003) Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk.Res., 27, 887-891.
954.Lapalombella R., Zhao X., Triantafillou G., Yu B., Jin Y., Lozanski G., Cheney C., Heerema N., Jarjoura D., Lehman A., Lee L.J., Marcucci G., Lee R.J., Caligiuri M.A., Muthusamy N., Byrd J.C. (2008) A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clin.Cancer Res., 14, 569-578.
955.Kirpotin D., Park J.W., Hong K., Zalipsky S., Li W.L., Carter P., Benz C.C., Papahadjopoulos D. (1997) Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry, 36, 66-75.
956.Sofou S., Kappel B.J., Jaggi J.S., McDevitt M.R., Scheinberg D.A., Sgouros G. (2007) Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers. Bioconjug.Chem., 18, 2061-2067.
957.Pan X., Wu G., Yang W., Barth R.F., Tjarks W., Lee R.J. (2007) Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug.Chem., 18, 101-108.
958.Hudson P.J., Souriau C. (2003) Engineered antibodies. Nat.Med., 9, 129-134.
959.Klibanov A.L., Muzykantov V.R., Ivanov N.N., Torchilin V.P. (1985) Evaluation of quantitative parameters of the interaction of antibody-bearing liposomes with target antigens.
Anal.Biochem., 150, 251-257.
960.Weiner L.M., Dhodapkar M.V., Ferrone S. (2009) Monoclonal antibodies for cancer immunotherapy. Lancet, 373, 1033-1040.
961.Waldmann T.A. (2003) Immunotherapy: past, present and future. Nat.Med., 9, 269-
962.Dutta R.C., Goldberg E. (2008) Testis specific lactate dehydrogenase as target for immunoliposomes. Am.J.Reprod.Immunol., 60, 26-32.
963.Sawant R.M., Cohen M.B., Torchilin V.P., Rokhlin O.W. (2008) Prostate cancerspecific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicinloaded liposomes against target cells in vitro. J.Drug Target, 16, 601-604.
964.Kim K.S., Lee Y.K., Kim J.S., Koo K.H., Hong H.J., Park Y.S. (2008) Targeted gene therapy of LS174 T human colon carcinoma by anti-TAG-72 immunoliposomes. Cancer Gene Ther., 15, 331-340.
254
965.Kim M.J., Lee H.J., Lee I.A., Kim I.Y., Lim S.K., Cho H.A., Kim J.S. (2008) Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes.
Arch.Pharm.Res., 31, 539-546.
966.Tuffin G., Huwyler J., Waelti E., Hammer C., Marti H.P. (2008) Drug targeting using OX7-immunoliposomes: correlation between Thy1.1 antigen expression and tissue distribution in the rat. J.Drug Target, 16, 156-166.
967.Gosk S., Moos T., Gottstein C., Bendas G. (2008) VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim.Biophys.Acta, 1778, 854-863.
968.Pattillo C.B., Venegas B., Donelson F.J., Del Valle L., Knight L.C., Chong P.L., Kiani M.F. (2009) Radiation-guided targeting of combretastatin encapsulated immunoliposomes to mammary tumors. Pharm.Res., 26, 1093-1100.
969.Чехонин В.П., Гурина О.И., Ухова О.В., Рябинина А.Е., Цибулькина Е.А., Жирков Ю.А. (2008) Иммунолипосомы, конъюгированные с полиэтиленгликолем, специфичные к обкладочным глиальным клеткам обонятельного эпителия.
Бюлл.Эксп.Биол.Мед., 145, 427-430.
970.Kostarelos K., Emfietzoglou D., Papakostas A., Yang W.H., Ballangrud A., Sgouros G. (2004) Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int.J.Cancer, 112, 713-721.
971.Kostarelos K., Emfietzoglou D., Papakostas A., Yang W.H., Ballangrud A.M., Sgouros G. (2005) Engineering lipid vesicles of enhanced intratumoral transport capabilities: correlating liposome characteristics with penetration into human prostate tumor spheroids.
J.Liposome Res., 15, 15-27.
972.Davies C.L., Lundstrom L.M., Frengen J., Eikenes L., Bruland S OS, Kaalhus O., Hjelstuen M.H., Brekken C. (2004) Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res., 64, 547-553.
973.Hosokawa S., Tagawa T., Niki H., Hirakawa Y., Nohga K., Nagaike K. (2003) Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner. Br.J.Cancer, 89, 1545-1551.
974.Marter A. (2001) Tumor angiogenesis as a therapeutic target. Drug Discov.Today, 6, 1005-1024.
975.Muller D., Trunk G., Sichelstiel A., Zettlitz K.A., Quintanilla M., Kontermann R.E. (2008) Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice. J.Immunol.Methods, 339, 90-98.
976.Zhang D., Feng X.Y., Henning T.D., Wen L., Lu W.Y., Pan H., Wu X., Zou L.G. (2009) MR imaging of tumor angiogenesis using sterically stabilized Gd-DTPA liposomes targeted to CD105. Eur.J.Radiol., 70, 180-189.
977.Elbayoumi T.A., Torchilin V.P. (2007) Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur.J.Pharm.Sci., 32, 159-168.
978.Gupta B., Levchenko T.S., Mongayt D.A., Torchilin V.P. (2005) Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo. J.Drug Target, 13, 337-343.
979.Lann-Terrisse A.D., Fournie G.J., Benoist H. (1997) Nucleosome-dependent escape of tumor cells from natural-killer-mediated lysis: nucleosomes are taken up by target cells and act at a postconjugation level. Cancer Immunol.Immunother., 43, 337-344.
980.Iakoubov L.Z., Torchilin V.P. (1998) Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. Cancer Detect.Prev., 22, 470-475.
981.Bagshawe K.D. (2009) Targeting: the ADEPT story so far. Curr.Drug Targets., 10, 152-157.
982.Bagshawe K.D. (2006) Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert.Rev.Anticancer Ther., 6, 1421-1431.
983.Jung M. (2001) Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy. Mini.Rev.Med.Chem., 1, 399-407.
984.Kratz F., Muller I.A., Ryppa C., Warnecke A. (2008) Prodrug strategies in anticancer chemotherapy. ChemMedChem., 3, 20-53.
255
985.Monks N.R., Blakey D.C., Curtin N.J., East S.J., Heuze A., Newell D.R. (2001) Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue. Br.J.Cancer, 85, 764-771.
986.Francis R.J., Sharma S.K., Springer C., Green A.J., Hope-Stone L.D., Sena L., Martin J., Adamson K.L., Robbins A., Gumbrell L., O'Malley D., Tsiompanou E., Shahbakhti H., Webley S., Hochhauser D., Hilson A.J., Blakey D., Begent R.H. (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br.J.Cancer, 87, 600-607.
987.Koning G.A., Morselt H.W., Velinova M.J., Donga J., Gorter A., Allen T.M., Zalipsky S., Kamps J.A., Scherphof G.L. (1999) Selective transfer of a lipophilic prodrug of 5- fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim.Biophys.Acta, 1420, 153-167.
988.Huysmans G., Ranquin A., Wyns L., Steyaert J., Van Gelder P. (2005) Encapsulation of therapeutic nucleoside hydrolase in functionalised nanocapsules. J.Control Release, 102, 171-179.
989.Vingerhoeds M.H., Haisma H.J., Belliot S.O., Smit R.H., Crommelin D.J., Storm G. (1996) Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. Pharm.Res., 13, 604-610.
990.Spragg D.D., Alford D.R., Greferath R., Larsen C.E., Lee K.D., Gurtner G.C., Cybulsky M.I., Tosi P.F., Nicolau C., Gimbrone M.A., Jr. (1997) Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc.Natl.Acad.Sci.U.S.A, 94, 8795-8800.
991.Tan P.H., Manunta M., Ardjomand N., Xue S.A., Larkin D.F., Haskard D.O., Taylor K.M., George A.J. (2003) Antibody targeted gene transfer to endothelium. J.Gene Med., 5, 311-323.
992.Xu L., Tang W.H., Huang C.C., Alexander W., Xiang L.M., Pirollo K.F., Rait A., Chang E.H. (2001) Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol.Med., 7, 723-734.
993.Yu W., Pirollo K.F., Rait A., Yu B., Xiang L.M., Huang W.Q., Zhou Q., Ertem G., Chang E.H. (2004) A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene. Gene Ther., 11, 1434-1440.
994.Yu W., Pirollo K.F., Yu B., Rait A., Xiang L., Huang W., Zhou Q., Ertem G., Chang E.H. (2004) Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res., 32, e48.
995.Rait A.S., Pirollo K.F., Ulick D., Cullen K., Chang E.H. (2003) HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents. Ann.N.Y.Acad.Sci., 1002, 78-89.
996.Pirollo K.F., Zon G., Rait A., Zhou Q., Yu W., Hogrefe R., Chang E.H. (2006) Tumortargeting nanoimmunoliposome complex for short interfering RNA delivery. Hum.Gene Ther., 17, 117-124.
997.Elbayoumi T.A., Torchilin V.P. (2006) Tumor-targeted immuno-lipisomes for delivery of therapeutics and diagnostics. Pharm.Eng., 26, 96-104.
998.Elbayoumi T.A., Pabba S., Roby A., Torchilin V.P. (2007) Antinucleosome antibodymodified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J.Liposome Res., 17, 1-14.
999.Emfietzoglou D., Kostarelos K., Papakostas A., Yang W.H., Ballangrud A., Song H., Sgouros G. (2005) Liposome-mediated radiotherapeutics within avascular tumor spheroids: comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody. J.Nucl.Med., 46, 89-97.
1000. Erdogan S., Roby A., Torchilin V.P. (2006) Enhanced tumor visualization by gammascintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes. Mol.Pharm., 3, 525-530.
1001. Erdogan S., Roby A., Sawant R., Hurley J., Torchilin V.P. (2006) Gadolinium-loaded polychelating polymer-containing cancer cell-specific immunoliposomes. J.Liposome Res., 16, 45-55.
256
1002. Kabalka G., Buonocore E., Hubner K., Moss T., Norley N., Huang L. (1987) Gadolinium-labeled liposomes: targeted MR contrast agents for the liver and spleen. Radiology, 163, 255-258.
1003. Kabalka G.W., Davis M.A., Moss T.H., Buonocore E., Hubner K., Holmberg E., Maruyama K., Huang L. (1991) Gadolinium-labeled liposomes containing various amphiphilic Gd-DTPA derivatives: targeted MRI contrast enhancement agents for the liver. Magn Reson.Med., 19, 406-415.
1004. Torchilin V.P. (2000) Polymeric contrast agents for medical imaging.
Curr.Pharm.Biotechnol., 1, 183-215.
1005. Jonasdottir T.J., Fisher D.R., Borrebaek J., Bruland O.S., Larsen R.H. (2006) First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent. Anticancer Res., 26, 2841-2848.
1006. Sofou S., Thomas J.L., Lin H.Y., McDevitt M.R., Scheinberg D.A., Sgouros G. (2004) Engineered liposomes for potential alpha-particle therapy of metastatic cancer. J.Nucl.Med., 45, 253-260.
1007. Matsumura Y., Gotoh M., Muro K., Yamada Y., Shirao K., Shimada Y., Okuwa M., Matsumoto S., Miyata Y., Ohkura H., Chin K., Baba S., Yamao T., Kannami A., Takamatsu Y., Ito K., Takahashi K. (2004) Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann.Oncol., 15, 517-525.
1008. Matsumura Y. (2003) An interim analysis of phase I clinical trial of MCC-465, a doxorubicin (DXR) encapsulated in PEG-immunoliposome, in patients with metastatic stomach cancer. Adv.Exp.Med.Biol., 519, 179-193.
1009. Lasic DL: (1997) "Liposomes in gene delivery". New York: CRC Press, Boca Raton. 1010. Torchilin V.P. (2006) Multifunctional nanocarriers. Adv.Drug Deliv.Rev., 58, 15321555.
1011. Torchilin V.P. (2006) Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu.Rev.Biomed.Eng, 8, 343-375.
1012. Haag R. (2004) Supramolecular drug-delivery systems based on polymeric core-shell architectures. Angew.Chem.Int.Ed Engl., 43, 278-282.
1013. Rijcken C.J., Soga O., Hennink W.E., van Nostrum C.F. (2007) Triggered destabilisation of polymeric micelles and vesicles by changing polymers polarity: an attractive tool for drug delivery. J.Control Release, 120, 131-148.
1014. Zhao Y. (2007) Rational design of light-controllable polymer micelles. Chem.Rec., 7, 286-294.
1015. Torchilin V.P. (2007) Nanocarriers. Pharm.Res., 24, 2333-2334.
1016. Lohmann D., Petrak K. (1989) Photoactivation and photocontrolled release of bioactive materials. Crit Rev.Ther.Drug Carrier Syst., 5, 263-320.
1017. Bhushan B. (2009) Biomimetics: lessons from nature – an overview . Philos.Transact.A Math.Phys.Eng Sci., 367, 1445-1486.
1018. Nosonovsky M., Bhushan B. (2009) Thermodynamics of surface degradation, selforganization and self-healing for biomimetic surfaces. Philos.Transact.A Math.Phys.Eng Sci., 367, 1607-1627.
1019. Buehler M.J., Ackbarow T. (2008) Nanomechanical strength mechanisms of hierarchical biological materials and tissues. Comput.Methods Biomech.Biomed.Engin., 11, 595-607.
1020. Sumaru K., Ohi K., Takagi T., Kanamori T., Shinbo T. (2006) Photoresponsive properties of poly(N-isopropylacrylamide) hydrogel partly modified with spirobenzopyran. Langmuir, 22, 4353-4356.
1021. Garcia A., Marquez M., Cai T., Rosario R., Hu Z., Gust D., Hayes M., Vail S.A., Park C.D. (2007) Photo-, thermally, and pH-responsive microgels. Langmuir, 23, 224-229.
1022. Alvarez-Lorenzo C., Concheiro A. (2008) Intelligent drug delivery systems: polymeric micelles and hydrogels. Mini.Rev.Med.Chem., 8, 1065-1074.
1023. Alvarez-Lorenzo C., Bromberg L., Concheiro A. (2009) Light-sensitive intelligent drug delivery systems. Photochem.Photobiol., 85, 848-860.
257
1024. Mochizuki-Oda N., Kataoka Y., Cui Y., Yamada H., Heya M., Awazu K. (2002) Effects of near-infra-red laser irradiation on adenosine triphosphate and adenosine diphosphate contents of rat brain tissue. Neurosci.Lett., 323, 207-210.
1025. Li Z., Zhang M., Zhang X., Dai S., Yu X., Wang Y. (2009) Assessment of cerebral oxygenation during prolonged simulated driving using near infrared spectroscopy: its implications for fatigue development. Eur.J.Appl.Physiol, 107, 281-287.
1026. Juzenas P., Juzeniene A., Kaalhus O., Iani V., Moan J. (2002) Noninvasive fluorescence excitation spectroscopy during application of 5-aminolevulinic acid in vivo.
Photochem.Photobiol.Sci., 1, 745-748.
1027. Klohs J., Wunder A., Licha K. (2008) Near-infrared fluorescent probes for imaging vascular pathophysiology. Basic Res.Cardiol., 103, 144-151.
1028. Yang Z., Leon J., Martin M., Harder J.W., Zhang R., Liang D., Lu W., Tian M., Gelovani J.G., Qiao A., Li C. (2009) Pharmacokinetics and biodistribution of near-infrared fluorescence polymeric nanoparticles. Nanotechnology, 20, 165101.
1029. Yong K.T. (2009) Mn-doped near-infrared quantum dots as multimodal targeted probes for pancreatic cancer imaging. Nanotechnology, 20, 15102.
1030. Chakravarti S., Srivastava S., Mittnacht A.J. (2008) Near infrared spectroscopy (NIRS) in children. Semin.Cardiothorac.Vasc.Anesth., 12, 70-79.
1031. Weissleder R., Ntziachristos V. (2003) Shedding light onto live molecular targets. Nat.Med., 9, 123-128.
1032. Hogset A., Prasmickaite L., Selbo P.K., Hellum M., Engesaeter B.O., Bonsted A., Berg K. (2004) Photochemical internalisation in drug and gene delivery. Adv.Drug Deliv.Rev., 56, 95-115.
1033. Prasmickaite L., Hogset A., Engesaeter B.B., Bonsted A., Berg K. (2004) Lightdirected gene delivery by photochemical internalisation. Expert.Opin.Biol.Ther., 4, 14031412.
1034. Shieh M.J., Peng C.L., Lou P.J., Chiu C.H., Tsai T.Y., Hsu C.Y., Yeh C.Y., Lai P.S. (2008) Non-toxic phototriggered gene transfection by PAMAM-porphyrin conjugates.
J.Control Release, 129, 200-206.
1035. Mojzisova H., Bonneau S., Maillard P., Berg K., Brault D. (2009) Photosensitizing properties of chlorins in solution and in membrane-mimicking systems. Photochem.Photobiol.Sci., 8, 778-787.
1036. Thompson D.H., Gerasimov O.V., Wheeler J.J., Rui Y., Anderson V.C. (1996) Triggerable plasmalogen liposomes: improvement of system efficiency. Biochim.Biophys.Acta, 1279, 25-34.
1037. Nishiyama N., Arnida, Jang W.D., Date K., Miyata K., Kataoka K. (2006) Photochemical enhancement of transgene expression by polymeric micelles incorporating plasmid DNA and dendrimer-based photosensitizer. J.Drug Target, 14, 413-424.
1038. Nishiyama N., Morimoto Y., Jang W.D., Kataoka K. (2009) Design and development of dendrimer photosensitizer-incorporated polymeric micelles for enhanced photodynamic therapy. Adv.Drug Deliv.Rev., 61, 327-338.
1039. Bondurant B., Mueller A., O'Brien D.F. (2001) Photoinitiated destabilization of sterically stabilized liposomes. Biochim.Biophys.Acta, 1511, 113-122.
1040. Spratt T., Bondurant B., O'Brien D.F. (2003) Rapid release of liposomal contents upon photoinitiated destabilization with UV exposure. Biochim.Biophys.Acta, 1611, 35-43.
1041. Henderson B.W., Dougherty T.J. (1992) How does photodynamic therapy work?
Photochem.Photobiol., 55, 145-157.
1042. Moan J., Juzenas P. (2006) Singlet oxygen in photosensitization.
J.Environ.Pathol.Toxicol.Oncol., 25, 29-50.
1043. Tarr M., Valenzeno D.P. (2003) Singlet oxygen: the relevance of extracellular production mechanisms to oxidative stress in vivo. Photochem.Photobiol.Sci., 2, 355-361. 1044. Moan J., Berg K. (1991) The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem.Photobiol., 53, 549-553.
1045. Endoh T., Ohtsuki T. (2009) Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv.Drug Deliv.Rev., 61, 704-709.
1046. Mudhakir D., Harashima H. (2009) Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus. AAPS.J., 11, 65-77.
258
1047. Oliveira S., Hogset A., Storm G., Schiffelers R.M. (2008) Delivery of siRNA to the target cell cytoplasm: photochemical internalization facilitates endosomal escape and improves silencing efficiency, in vitro and in vivo. Curr.Pharm.Des, 14, 3686-3697.
1048. White P.J. (2008) Barriers to successful delivery of short interfering RNA after systemic administration. Clin.Exp.Pharmacol.Physiol, 35, 1371-1376.
1049. Berg K., Bommer J.C., Winkelman J.W., Moan J. (1990) Cellular uptake and relative efficiency in cell inactivation by photoactivated sulfonated meso-tetraphenylporphines.
Photochem.Photobiol., 52, 775-781.
1050. Rosenkranz A.A., Jans D.A., Sobolev A.S. (2000) Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency. Immunol.Cell Biol., 78, 452-464.
1051. Prasmickaite L., Hogset A., Berg K. (2001) Evaluation of different photosensitizers for use in photochemical gene transfection. Photochem.Photobiol., 73, 388-395.
1052. Berg K., Moan J. (1994) Lysosomes as photochemical targets. Int.J.Cancer, 59, 814822.
1053. Maman N., Dhami S., Phillips D., Brault D. (1999) Kinetic and equilibrium studies of incorporation of di-sulfonated aluminum phthalocyanine into unilamellar vesicles. Biochim.Biophys.Acta, 1420, 168-178.
1054. Moghissi K., Dixon K. (2008) Update on the current indications, practice and results of photodynamic therapy (PDT) in early central lung cancer (ECLC). Photodiagnosis.Photodyn.Ther., 5, 10-18.
1055. Donnelly R.F., McCarron P.A., Morrow D.I., Sibani S.A., Woolfson A.D. (2008) Photosensitiser delivery for photodynamic therapy. Part 1: Topical carrier platforms.
Expert.Opin.Drug Deliv., 5, 757-766.
1056. Wainwright M. (2008) Photodynamic therapy: the development of new photosensitisers. Anticancer Agents Med.Chem., 8, 280-291.
1057. Norum O.J., Selbo P.K., Weyergang A., Giercksky K.E., Berg K. (2009) Photochemical internalization (PCI) in cancer therapy: from bench towards bedside medicine.
J.Photochem.Photobiol.B, 96, 83-92.
1058. Norum O.J., Giercksky K.E., Berg K. (2009) Photochemical internalization as an adjunct to marginal surgery in a human sarcoma model. Photochem.Photobiol.Sci., 8, 758762.
1059. Selbo P.K., Weyergang A., Bonsted A., Bown S.G., Berg K. (2006) Photochemical internalization of therapeutic macromolecular agents: a novel strategy to kill multidrugresistant cancer cells. J.Pharmacol.Exp.Ther., 319, 604-612.
1060. Berg K., Dietze A., Kaalhus O., Hogset A. (2005) Site-specific drug delivery by photochemical internalization enhances the antitumor effect of bleomycin. Clin.Cancer Res., 11, 8476-8485.
1061. Cabral H., Nakanishi M., Kumagai M., Jang W.D., Nishiyama N., Kataoka K. (2009) A photo-activated targeting chemotherapy using glutathione sensitive camptothecin-loaded polymeric micelles. Pharm.Res., 26, 82-92.
1062. Lou P.J., Lai P.S., Shieh M.J., MacRobert A.J., Berg K., Bown S.G. (2006) Reversal of doxorubicin resistance in breast cancer cells by photochemical internalization. Int.J.Cancer, 119, 2692-2698.
1063. Lai P.S., Lou P.J., Peng C.L., Pai C.L., Yen W.N., Huang M.Y., Young T.H., Shieh M.J. (2007) Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. J.Control Release, 122, 39-46.
1064. Lai P.S., Pai C.L., Peng C.L., Shieh M.J., Berg K., Lou P.J. (2008) Enhanced cytotoxicity of saporin by polyamidoamine dendrimer conjugation and photochemical internalization. J.Biomed.Mater.Res.A, 87, 147-155.
1065. Fretz M.M., Hogset A., Koning G.A., Jiskoot W., Storm G. (2007) Cytosolic delivery of liposomally targeted proteins induced by photochemical internalization. Pharm.Res., 24, 2040-2047.
1066. Yip W.L., Weyergang A., Berg K., Tonnesen H.H., Selbo P.K. (2007) Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells. Mol.Pharm., 4, 241-251.
1067. Ndoye A., Dolivet G., Hogset A., Leroux A., Fifre A., Erbacher P., Berg K., Behr J.P., Guillemin F., Merlin J.L. (2006) Eradication of p53-mutated head and neck squamous cell